PH26155A - Pharmaceutical composition piperidinoalkanol-decongestant combination - Google Patents
Pharmaceutical composition piperidinoalkanol-decongestant combination Download PDFInfo
- Publication number
- PH26155A PH26155A PH37643A PH37643A PH26155A PH 26155 A PH26155 A PH 26155A PH 37643 A PH37643 A PH 37643A PH 37643 A PH37643 A PH 37643A PH 26155 A PH26155 A PH 26155A
- Authority
- PH
- Philippines
- Prior art keywords
- formulation
- carrier base
- amount
- composition
- base material
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 19
- 239000000850 decongestant Substances 0.000 title claims description 12
- 239000000203 mixture Substances 0.000 claims description 112
- 238000009472 formulation Methods 0.000 claims description 76
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 18
- 238000007906 compression Methods 0.000 claims description 18
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 12
- 239000000739 antihistaminic agent Substances 0.000 claims description 11
- 230000006835 compression Effects 0.000 claims description 11
- -1 hydroxypropylmethyl Chemical group 0.000 claims description 10
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 claims description 10
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 claims description 10
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 7
- 230000001387 anti-histamine Effects 0.000 claims description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 239000003945 anionic surfactant Substances 0.000 claims description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 5
- 229940068968 polysorbate 80 Drugs 0.000 claims description 5
- 229960003908 pseudoephedrine Drugs 0.000 claims description 4
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 55
- 238000005469 granulation Methods 0.000 description 21
- 230000003179 granulation Effects 0.000 description 21
- 229940127230 sympathomimetic drug Drugs 0.000 description 20
- 239000008187 granular material Substances 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000150 Sympathomimetic Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000007942 layered tablet Substances 0.000 description 6
- 239000002736 nonionic surfactant Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- 241000237858 Gastropoda Species 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229940125715 antihistaminic agent Drugs 0.000 description 4
- 229920003086 cellulose ether Polymers 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920003091 Methocel™ Polymers 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 3
- YRISKTNAYHHICR-UHFFFAOYSA-N 4-piperidin-1-ylbutan-1-ol Chemical compound OCCCCN1CCCCC1 YRISKTNAYHHICR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028735 Nasal congestion Diseases 0.000 description 2
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 238000009491 slugging Methods 0.000 description 2
- VILMUCRZVVVJCA-UHFFFAOYSA-M sodium glycolate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 description 2
- 229940071117 starch glycolate Drugs 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100028085 Glycylpeptide N-tetradecanoyltransferase 1 Human genes 0.000 description 1
- 101710081880 Glycylpeptide N-tetradecanoyltransferase 1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920003094 Methocel™ K4M Polymers 0.000 description 1
- 241000528415 Moana Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229910052936 alkali metal sulfate Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- NVVZQXQBYZPMLJ-UHFFFAOYSA-N formaldehyde;naphthalene-1-sulfonic acid Chemical compound O=C.C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 NVVZQXQBYZPMLJ-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- ONQDVAFWWYYXHM-UHFFFAOYSA-M potassium lauryl sulfate Chemical compound [K+].CCCCCCCCCCCCOS([O-])(=O)=O ONQDVAFWWYYXHM-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10593987A | 1987-10-07 | 1987-10-07 | |
US21130888A | 1988-06-24 | 1988-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PH26155A true PH26155A (en) | 1992-03-18 |
Family
ID=26803117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH37643A PH26155A (en) | 1987-10-07 | 1988-10-05 | Pharmaceutical composition piperidinoalkanol-decongestant combination |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0311067B1 (es) |
JP (1) | JP2722219B2 (es) |
KR (1) | KR960007748B1 (es) |
CN (1) | CN1053570C (es) |
AU (1) | AU608069B2 (es) |
CA (1) | CA1314485C (es) |
DE (1) | DE3874072T2 (es) |
DK (1) | DK168270B1 (es) |
ES (1) | ES2046270T3 (es) |
FI (1) | FI89241C (es) |
GR (1) | GR3005542T3 (es) |
HU (1) | HU200916B (es) |
IE (1) | IE61130B1 (es) |
IL (1) | IL87943A (es) |
NO (1) | NO176746C (es) |
NZ (1) | NZ226482A (es) |
PH (1) | PH26155A (es) |
PT (1) | PT88682B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5314697A (en) * | 1992-10-23 | 1994-05-24 | Schering Corporation | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
SK279684B6 (sk) * | 1993-06-14 | 1999-02-11 | Janssen Pharmaceutica N.V. | Tableta a spôsob jej výroby |
WO1996026726A1 (en) | 1995-02-28 | 1996-09-06 | Hoechst Marion Roussel, Inc. | Pharmaceutical composition for piperidinoalkanol compounds |
EP0823255A4 (en) * | 1995-04-03 | 1999-01-27 | Chugai Pharmaceutical Co Ltd | MEDICINAL PRODUCT CONTAINING SUCRAL FATE |
EP0811374A1 (en) | 1996-05-29 | 1997-12-10 | Pfizer Inc. | Combination dosage form comprising cetirizine and pseudoephedrine |
AU725811B2 (en) * | 1997-08-26 | 2000-10-19 | Aventisub Llc | Pharmaceutical composition for combination of piperidinoalkanol-decongestant |
US6194431B1 (en) | 1998-04-14 | 2001-02-27 | Paul D. Rubin | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
US6232351B1 (en) * | 1998-05-22 | 2001-05-15 | Amway Corporation | Co-processed botanical plant composition |
US6267986B1 (en) * | 1999-09-24 | 2001-07-31 | Ranbaxy Laboratories Limited | Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine |
US20020094345A1 (en) | 2000-10-06 | 2002-07-18 | Sara Abelaira | Pharmaceutical compositions containing epinastine and pseudoephedrine |
EP2121031B1 (en) * | 2007-03-12 | 2013-10-16 | Nektar Therapeutics | Oligomer-antihistamine conjugates |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3558768A (en) * | 1969-12-19 | 1971-01-26 | Sterling Drug Inc | Sustained release pharmaceutical compositions |
US3878217A (en) | 1972-01-28 | 1975-04-15 | Richardson Merrell Inc | Alpha-aryl-4-substituted piperidinoalkanol derivatives |
US4285957A (en) | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof |
US4254129A (en) | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
JPS5788117A (en) * | 1980-11-21 | 1982-06-01 | Smithkline Corp | Gelatin capsule containing triamterene |
JPS5877810A (ja) * | 1981-11-01 | 1983-05-11 | Taiho Yakuhin Kogyo Kk | ポリグリセロ−ル不飽和脂肪酸エステルを含む経口薬剤組成物 |
IT1198386B (it) * | 1982-07-06 | 1988-12-21 | Lepetit Spa | Un prodotto a rilascio protratto contenente il suloctidile |
ZA838033B (en) * | 1982-11-01 | 1984-06-27 | Merrell Dow Pharma | Sustained release solid dosage forms having non-uniform distribution of active ingredient |
IL70071A (en) * | 1982-11-01 | 1987-12-31 | Merrell Dow Pharma | Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient |
ZA845180B (en) * | 1983-07-07 | 1986-02-26 | American Home Prod | Pharmaceutical composition containing a liquid lubricant |
-
1988
- 1988-09-30 CN CN88106981A patent/CN1053570C/zh not_active Expired - Lifetime
- 1988-10-03 FI FI884545A patent/FI89241C/fi not_active IP Right Cessation
- 1988-10-04 CA CA000579286A patent/CA1314485C/en not_active Expired - Lifetime
- 1988-10-05 PH PH37643A patent/PH26155A/en unknown
- 1988-10-05 JP JP63250047A patent/JP2722219B2/ja not_active Expired - Lifetime
- 1988-10-05 AU AU23459/88A patent/AU608069B2/en not_active Expired
- 1988-10-06 EP EP88116540A patent/EP0311067B1/en not_active Expired - Lifetime
- 1988-10-06 DE DE8888116540T patent/DE3874072T2/de not_active Expired - Lifetime
- 1988-10-06 ES ES198888116540T patent/ES2046270T3/es not_active Expired - Lifetime
- 1988-10-06 NO NO884443A patent/NO176746C/no not_active IP Right Cessation
- 1988-10-06 IE IE303388A patent/IE61130B1/en not_active IP Right Cessation
- 1988-10-06 PT PT88682A patent/PT88682B/pt not_active IP Right Cessation
- 1988-10-06 HU HU885184A patent/HU200916B/hu unknown
- 1988-10-06 IL IL87943A patent/IL87943A/xx active Protection Beyond IP Right Term
- 1988-10-06 DK DK559088A patent/DK168270B1/da active IP Right Grant
- 1988-10-06 NZ NZ226482A patent/NZ226482A/xx unknown
- 1988-10-07 KR KR1019880013062A patent/KR960007748B1/ko not_active IP Right Cessation
-
1992
- 1992-08-27 GR GR920401871T patent/GR3005542T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0311067A1 (en) | 1989-04-12 |
DK559088D0 (da) | 1988-10-06 |
IL87943A (en) | 1992-02-16 |
AU2345988A (en) | 1989-04-20 |
DE3874072T2 (de) | 1993-04-08 |
NO884443L (no) | 1989-04-10 |
JP2722219B2 (ja) | 1998-03-04 |
FI884545A0 (fi) | 1988-10-03 |
ES2046270T3 (es) | 1994-02-01 |
NO176746B (no) | 1995-02-13 |
EP0311067B1 (en) | 1992-08-26 |
PT88682A (pt) | 1988-11-01 |
CA1314485C (en) | 1993-03-16 |
GR3005542T3 (es) | 1993-06-07 |
CN1053570C (zh) | 2000-06-21 |
DE3874072D1 (de) | 1992-10-01 |
IL87943A0 (en) | 1989-03-31 |
CN1032738A (zh) | 1989-05-10 |
DK168270B1 (da) | 1994-03-07 |
HU200916B (en) | 1990-09-28 |
AU608069B2 (en) | 1991-03-21 |
DK559088A (da) | 1989-04-08 |
JPH01128925A (ja) | 1989-05-22 |
IE883033L (en) | 1989-04-07 |
PT88682B (pt) | 1992-12-31 |
KR960007748B1 (ko) | 1996-06-12 |
NZ226482A (en) | 1990-09-26 |
FI884545A (fi) | 1989-04-08 |
NO884443D0 (no) | 1988-10-06 |
KR890006236A (ko) | 1989-06-12 |
IE61130B1 (en) | 1994-10-05 |
FI89241C (fi) | 1993-09-10 |
FI89241B (fi) | 1993-05-31 |
HUT48816A (en) | 1989-07-28 |
NO176746C (no) | 1995-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4996061A (en) | Pharmaceutical composition for piperidinoalkanol-decongestant combination | |
US4999226A (en) | Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination | |
EP1382331B1 (en) | A pharmaceutical tablet characterized by showing a high volume increase when coming into contact with biological fluids | |
KR101465077B1 (ko) | 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물 | |
PL196668B1 (pl) | Zastosowanie ranolazyny do wytwarzania kompozycji farmaceutycznej o przedłużonym uwalnianiu | |
US5814339A (en) | Film coated tablet of paracetamol and domperidone | |
EP0311067B1 (en) | Pharmaceutical composition for piperidinoalkanol-decongestant combination | |
WO2010128525A2 (en) | A formulation of ivabradine for treating the cardiovascular disease | |
WO1995022320A1 (en) | Ranitidine solid dosage form | |
KR101512386B1 (ko) | 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 | |
US20080095846A1 (en) | Pharmaceutical compositions of antihistamine and decongestant | |
WO1999002142A2 (en) | Novel composition comprising an ssri and a beta-blocker | |
EP1490034B1 (en) | Novel pharmaceutical compositions for antihistaminic-decongestant combination and method of making such compositions | |
BG107686A (bg) | Нови фармацевтични състави, съдържащи епинастин ипсевдоефедрин | |
KR101591357B1 (ko) | 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 | |
KR20200104265A (ko) | 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제 |